Literature DB >> 22890997

Role of interleukin-32 in Helicobacter pylori-induced gastric inflammation.

Kosuke Sakitani1, Yoshihiro Hirata, Yoku Hayakawa, Takako Serizawa, Wachiko Nakata, Ryota Takahashi, Hiroto Kinoshita, Kei Sakamoto, Hayato Nakagawa, Masao Akanuma, Haruhiko Yoshida, Shin Maeda, Kazuhiko Koike.   

Abstract

Helicobacter pylori infection is associated with gastritis and gastric cancer. An H. pylori virulence factor, the cag pathogenicity island (PAI), is related to host cell cytokine induction and gastric inflammation. Since elucidation of the mechanisms of inflammation is important for therapy, the associations between cytokines and inflammatory diseases have been investigated vigorously. Levels of interleukin-32 (IL-32), a recently described inflammatory cytokine, are increased in various inflammatory diseases, such as rheumatoid arthritis and Crohn's disease, and in malignancies, including gastric cancer. In this report, we examined IL-32 expression in human gastric disease. We also investigated the function of IL-32 in activation of the inflammatory cytokines in gastritis. IL-32 expression paralleled human gastric tissue pathology, with low IL-32 expression in H. pylori-uninfected gastric mucosa and higher expression levels in gastritis and gastric cancer tissues. H. pylori infection increased IL-32 expression in human gastric epithelial cell lines. H. pylori-induced IL-32 expression was dependent on the bacterial cagPAI genes and on activation of nuclear factor κB (NF-κB). IL-32 expression induced by H. pylori was not detected in the supernatant of AGS cells but was found in the cytosol. Expression of the H. pylori-induced cytokines CXCL1, CXCL2, and IL-8 was decreased in IL-32-knockdown AGS cell lines compared to a control AGS cell line. We also found that NF-κB activation was decreased in H. pylori-infected IL-32-knockdown cells. These results suggest that IL-32 has important functions in the regulation of cytokine expression in H. pylori-infected gastric mucosa.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22890997      PMCID: PMC3486038          DOI: 10.1128/IAI.00637-12

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

Review 1.  NF-kappaB at the crossroads of life and death.

Authors:  Michael Karin; Anning Lin
Journal:  Nat Immunol       Date:  2002-03       Impact factor: 25.606

2.  Native IL-32 is released from intestinal epithelial cells via a non-classical secretory pathway as a membrane-associated protein.

Authors:  Haruki Hasegawa; Heather J Thomas; Ken Schooley; Teresa L Born
Journal:  Cytokine       Date:  2011-01       Impact factor: 3.861

3.  Helicobacter pylori induced transactivation of SRE and AP-1 through the ERK signalling pathway in gastric cancer cells.

Authors:  Y Mitsuno; H Yoshida; S Maeda; K Ogura; Y Hirata; T Kawabe; Y Shiratori; M Omata
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

4.  Helicobacter pylori infection and the development of gastric cancer.

Authors:  N Uemura; S Okamoto; S Yamamoto; N Matsumura; S Yamaguchi; M Yamakido; K Taniyama; N Sasaki; R J Schlemper
Journal:  N Engl J Med       Date:  2001-09-13       Impact factor: 91.245

5.  Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori.

Authors:  E D Segal; J Cha; J Lo; S Falkow; L S Tompkins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

6.  Distinct mechanism of Helicobacter pylori-mediated NF-kappa B activation between gastric cancer cells and monocytic cells.

Authors:  S Maeda; M Akanuma; Y Mitsuno; Y Hirata; K Ogura; H Yoshida; Y Shiratori; M Omata
Journal:  J Biol Chem       Date:  2001-08-23       Impact factor: 5.157

7.  Helicobacter pylori CagA protein activates serum response element-driven transcription independently of tyrosine phosphorylation.

Authors:  Yoshihiro Hirata; Shin Maeda; Yuzo Mitsuno; Keisuke Tateishi; Ayako Yanai; Masao Akanuma; Haruhiko Yoshida; Takao Kawabe; Yasushi Shiratori; Masao Omata
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

8.  H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells.

Authors:  S Maeda; H Yoshida; K Ogura; Y Mitsuno; Y Hirata; Y Yamaji; M Akanuma; Y Shiratori; M Omata
Journal:  Gastroenterology       Date:  2000-07       Impact factor: 22.682

9.  Helicobacter pylori activates the cyclin D1 gene through mitogen-activated protein kinase pathway in gastric cancer cells.

Authors:  Y Hirata; S Maeda; Y Mitsuno; M Akanuma; Y Yamaji; K Ogura; H Yoshida; Y Shiratori; M Omata
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

Review 10.  Infliximab treatment of rheumatoid arthritis and Crohn's disease.

Authors:  Ibrahim K Nahar; Kam Shojania; Carlo A Marra; Abul H Alamgir; Aslam H Anis
Journal:  Ann Pharmacother       Date:  2003-09       Impact factor: 3.154

View more
  25 in total

1.  Dendritic Cell-Derived IL-32α: A Novel Inhibitory Cytokine of NK Cell Function.

Authors:  Laurent Gorvel; Daniel Korenfeld; Thomas Tung; Eynav Klechevsky
Journal:  J Immunol       Date:  2017-07-12       Impact factor: 5.422

Review 2.  The Importance of CXCL1 in the Physiological State and in Noncancer Diseases of the Oral Cavity and Abdominal Organs.

Authors:  Jan Korbecki; Iwona Szatkowska; Patrycja Kupnicka; Wojciech Żwierełło; Katarzyna Barczak; Iwona Poziomkowska-Gęsicka; Jerzy Wójcik; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

Review 3.  IL-32θ: a recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity.

Authors:  Muhammad Babar Khawar; Maryam Mukhtar; Muddasir Hassan Abbasi; Nadeem Sheikh
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

Review 4.  CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targeting.

Authors:  Hyo Jin Lee; Ik-Chan Song; Hwan-Jung Yun; Deog-Yeon Jo; Samyong Kim
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

5.  Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer.

Authors:  Kayhan Erturk; Didem Tastekin; Murat Serilmez; Elif Bilgin; Hamza Ugur Bozbey; Sezai Vatansever
Journal:  Tumour Biol       Date:  2015-07-29

Review 6.  Novel insights into the biology of interleukin-32.

Authors:  Leo A B Joosten; Bas Heinhuis; Mihai G Netea; Charles A Dinarello
Journal:  Cell Mol Life Sci       Date:  2013-03-06       Impact factor: 9.261

Review 7.  Helicobacter pylori in gastric carcinogenesis: mechanisms.

Authors:  Lydia E Wroblewski; Richard M Peek
Journal:  Gastroenterol Clin North Am       Date:  2013-03-06       Impact factor: 3.806

8.  Differential roles of ASK1 and TAK1 in Helicobacter pylori-induced cellular responses.

Authors:  Yoku Hayakawa; Yoshihiro Hirata; Hiroto Kinoshita; Kosuke Sakitani; Hayato Nakagawa; Wachiko Nakata; Ryota Takahashi; Kei Sakamoto; Shin Maeda; Kazuhiko Koike
Journal:  Infect Immun       Date:  2013-09-30       Impact factor: 3.441

9.  Staphylococcus aureus Phenol-Soluble Modulins Impair Interleukin Expression in Bovine Mammary Epithelial Cells.

Authors:  Martine Deplanche; Ludmila Alekseeva; Ksenia Semenovskaya; Chih-Lung Fu; Frederic Dessauge; Laurence Finot; Wolfram Petzl; Holm Zerbe; Yves Le Loir; Pascal Rainard; David G E Smith; Pierre Germon; Michael Otto; Nadia Berkova
Journal:  Infect Immun       Date:  2016-05-24       Impact factor: 3.441

Review 10.  Cytokines, cytokine gene polymorphisms and Helicobacter pylori infection: friend or foe?

Authors:  Camila A Figueiredo; Cintia Rodrigues Marques; Ryan dos Santos Costa; Hugo Bernardino F da Silva; Neuza M Alcantara-Neves
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.